Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy

Immune checkpoint inhibitors (ICIs) have activity across many tumor types, but activation of the immune system may also lead to significant, often steroid-refractory immune-related adverse events (irAEs). We sought to determine the activity of tocilizumab, an anti-interleukin-6 receptor monoclonal a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) Jg. 157; S. 214 - 224
Hauptverfasser:	Dimitriou, Florentia, Hogan, Sabrina, Menzies, Alexander M., Dummer, Reinhard, Long, Georgina V.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.11.2021 Elsevier Science Ltd
Schlagworte:	Adult Adverse events Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Autoimmune diseases Autoimmune Diseases - complications Autoimmune Diseases - diagnosis Autoimmune Diseases - immunology Autoimmune Diseases - prevention & control C-reactive protein C-Reactive Protein - analysis Cancer Cancer immunotherapy Clinical trials Cytokines Drug-Related Side Effects and Adverse Reactions - blood Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - drug therapy Drug-Related Side Effects and Adverse Reactions - immunology Evaluation Female Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune system Immune-related adverse events Immunotherapy Inflammatory reaction Interleukin 6 Interleukin-6 - antagonists & inhibitors Male Melanoma Melanoma - complications Melanoma - drug therapy Melanoma - immunology Middle Aged Monoclonal antibodies Patients Prevention Prophylaxis Prospective Studies Retrospective Studies Skin Neoplasms - complications Skin Neoplasms - drug therapy Skin Neoplasms - immunology Steroids Survival Symptom Flare Up Tocilizumab Toxicity Tumors Immune-related adverse events Tocilizumab Inflammatory reaction Immunotherapy
ISSN:	0959-8049, 1879-0852, 1879-0852
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!